Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 1,760,000 shares, a growth of 7,025.5% from the May 31st total of 24,700 shares. Based on an average daily volume of 467,900 shares, the short-interest ratio is currently 3.8 days. Approximately 58.9% of the shares of the company are sold short.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Armistice Capital LLC increased its position in shares of Tonix Pharmaceuticals by 160.0% in the 4th quarter. Armistice Capital LLC now owns 3,770,000 shares of the company’s stock valued at $1,519,000 after acquiring an additional 2,320,000 shares during the period. Sabby Management LLC acquired a new stake in Tonix Pharmaceuticals during the 3rd quarter worth about $680,000. Finally, Acadian Asset Management LLC grew its position in Tonix Pharmaceuticals by 260.6% during the 1st quarter. Acadian Asset Management LLC now owns 335,373 shares of the company’s stock worth $61,000 after purchasing an additional 242,358 shares during the period. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Stock Up 0.7 %

Shares of TNXP stock traded up $0.01 on Friday, hitting $0.70. The stock had a trading volume of 1,141,783 shares, compared to its average volume of 352,509. The company has a quick ratio of 0.87, a current ratio of 1.47 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $4.22 and a 200 day moving average price of $8.35. The company has a market cap of $2.08 million, a PE ratio of 0.00 and a beta of 2.16. Tonix Pharmaceuticals has a one year low of $0.60 and a one year high of $60.16.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Monday, May 13th. The company reported ($5.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($16.64) by $10.88. The company had revenue of $2.48 million during the quarter, compared to analysts’ expectations of $4.00 million. Research analysts anticipate that Tonix Pharmaceuticals will post -82.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Friday, June 14th. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.